Moleculin Biotech, Inc. (MBRX)
Fuera de horario:
Moleculin Biotech, Inc.
5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
(713) 300-5160
https://moleculin.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 18
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Walter V. Klemp | Founder, Chairman, President & CEO | 894.54k | N/D | 1960 |
| Mr. Jonathan P. Foster CPA | Executive VP & CFO | 611.17k | N/D | 1964 |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer | 486.44k | N/D | 1946 |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board | N/D | N/D | N/D |
Descripción
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Moleculin Biotech, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
